IXICO

This week, from September 18-20th, we will attend ECTRIMS in Copenhagen, Denmark! Here's a refresher of who's attending from IXICO: Kirsi Kinnunen will be presenting a poster on our latest work in understanding multiple sclerosis progression: 🕛 Poster Session 2 Session Date: Thursday, 19 September 2024 Session Time: 16.45 – 18.45 CEST 🧠 Poster P904 - Fully automatic detection and quantification of new white matter lesions using deep learning She will be at ECTRIMS to share imaging biomarker insights and learn from others in the MS clinical research field. Drop us a message if you're going to ECTRIMS! Maybe we can schedule a time to talk! See you in Copenhagen!

🔬 Neuroimaging to Facilitate Clinical Trials in Huntington’s Disease: Current Opinion from the EHDN Imaging Working Group - IOS Press 🧠 In the evolving landscape of Huntington’s disease (HD) clinical trials, there is a growing emphasis on precision and efficacy. Neuroimaging has emerged as a pivotal tool, offering unparalleled insights that enhance various aspects of trial design and execution. This comprehensive overview delves into the critical roles of structural, functional, and diffusion MRI, PET, MRS, and MEG in Huntington’s disease clinical trials. Key Highlights: ➡️Patient Selection: Enhancing precision in choosing trial participants. ➡️Safety Monitoring: Ensuring patient safety throughout the trial. ➡️Efficacy Demonstration: Proving the effectiveness of treatments. Challenges Addressed: ➡️Equipment requirements ➡️Standardization of procedures ➡️Managing patient burden ➡️Interpreting complex data This resource is invaluable for professionals involved in the design and execution of clinical trials, providing insights into effectively integrating neuroimaging methodologies. Special thanks to the authors: Nicola Hobbs, PhD, Marina Papoutsi, Aline Delva, Kirsi Kinnunen, Mitsuko Nakajima, Koen Van Laere, @Wim Vandenberghe, Priyantha Herath, and Rachael Scahill. Read more: https://lnkd.in/dhbzjg5Q

Next week, on September 12-14th, we will be at the European Huntington's Disease Network (EHDN) in Strasbourg, France! Marina Papoutsi will be presenting a poster on our latest work in understanding Huntington's disease progression: 🕛 September 12th - 12PM onwards 🧠 Poster E020 Volumetric change across the different Stages of the Huntington’s disease Integrated Staging System (HD-ISS) defined at baseline Roxanne Langlois will be with Marina to share imaging biomarker insights and learn from others in the Huntington's disease clinical research field. Drop us a message if you're going to EHDN - We'd love to connect! See you in Strasbourg!

Next month, on September 18-20th, we will attend ECTRIMS in Copenhagen, Denmark! Kirsi Kinnunen will be presenting a poster on our latest work in understanding multiple sclerosis progression: 🕛 Poster Session 2 Session Date: Thursday, 19 September 2024 Session Time: 16.45 – 18.45 CEST 🧠 Poster P904 - Fully automatic detection and quantification of new white matter lesions using deep learning Kirsi will be at ECTRIMS to share imaging biomarker insights and learn from others in the MS clinical research field. So whether you're an old or new friend, stop by and say hello! Drop us a message if you're going to ECTRIMS! Maybe we can schedule a time to talk! See you in Copenhagen!

On September 12-14th, we will be attending the European Huntington's Disease Network (EHDN) in Strasbourg, France! Marina Papoutsi will be presenting a poster on our latest work in understanding Huntington's disease progression: 🕛 September 12th - 12PM onwards 🧠 Poster E020 Volumetric change across the different Stages of the Huntington’s disease Integrated Staging System (HD-ISS) defined at baseline Roxanne Langlois will be with Marina to share imaging biomarker insights and learn from others in the Huntington's disease clinical research field. So whether you're an old or new friend, stop by and say hello! Drop us a message if you're going to EHDN! Maybe we can schedule a time to talk! See you in Strasbourg!

IXICO is pleased to announce that Bram Goorden will be appointed as Chief Executive Officer of the Company from 19 August 2024. Bram has over 20 years leadership experience in BioPharma and precision medicine, serving in roles where he has been instrumental in shaping commercial strategies for scale, growing revenues and ultimately enabling realisation of shareholder value. He has strong CNS experience, and established networks within IXICO's target market bringing sector relevant strength to IXICO. Bram joins having recently held C-level roles at Eagle Genomics Limited where he drove key industry alliances for their AI platform and NASDAQ listed SOPHiA Genetics Inc where he expanded their US footprint and delivered key alliances with Pharma. In previous roles as VP International Business, he expanded Foundation Medicine Inc's global presence in precision medicine including programs with major BioPharma partners, and as division CEO of US-based Prometheus Laboratories he delivered shareholder value via the integration of the company into Nestle Health Science SA. Bram has also held senior management positions within UCB Pharma SA and Eli Lilly & Co, both in the field of CNS medicine. Mark Warne, Chair of the Board, commented: "I am delighted to welcome Bram to the Board as our CEO. Bram has significant track record in the commercial application of AI precision medicine solutions that is complemented by technical knowledge within neurodegenerative diseases. As IXICO looks to return to growth, Bram's experiences provide excellent credentials to ensure IXICO also realises shareholder value. I would like to thank Giulio Cerroni for his valuable contributions over many years. Having joined IXICO in 2017, Giulio steered the company through a period of both strong growth and more challenging trading conditions. He has overseen the development of the company's science and technology portfolio which, in combination with IXICO's operational capabilities, ensure the consistent delivery of leading services to the CNS clinical trials market." For more information on the appointment, please visit: https://lnkd.in/ervc9w7t

Thank you to everyone who met with us during Alzheimer's Association® annual AAIC meeting in Philadephia, PA! Robin Wolz and Scott Vogel had many brilliant conversations with the AD community and hope to continue them long after the conference! In case you missed our poster presentations yesterday, we'll put our posters on our website in the coming weeks and inform you of their availability via our team and LinkedIn. See you at next year's AAIC in Toronto, Canada!

Next week, starting Sunday, July 28th, We’ll be at AAIC hosted by Alzheimer's Association® until August 1st in Philadelphia, USA! Here's a recap of what to expect from us at AAIC: Robin Wolz will be presenting posters on our latest work in understanding Alzheimer's disease progression: 🕛 Wednesday, July 31, 2024: 7:30 AM – 4:15 PM EDT 🧠 Poster #86084 Erosion of The Supratentorial White Matter Reference for Increased Power in Longitudinal Amyloid PET 🧠 Poster #92157 Comparison of local amyloid PET uptake patterns between black and white participants in the GAP Bio-Hermes study Scott Vogel will be with Robin to share imaging biomarker insights and learn from others in the Alzheimer's disease clinical research field. So whether you're an old or new friend, stop by and say hello! Drop us a message if you're going to AAIC! Maybe we can schedule a time to talk! See you in Philadelphia!

We’ll be at AAIC hosted by Alzheimer's Association® on July 28th – August 1st in Philadelphia, USA! Robin Wolz will be presenting posters on our latest work in understanding Alzheimer's disease progression: 🕛 Wednesday, July 31, 2024: 7:30 AM – 4:15 PM EDT 🧠 Poster #86084  Erosion of The Supratentorial White Matter Reference for Increased Power in Longitudinal Amyloid PET 🧠 Poster #92157  Comparison of local amyloid PET uptake patterns between black and white participants in the GAP Bio-Hermes study Scott Vogel will join Robin to share imaging biomarker insights and learn from others in the Alzheimer's disease clinical research field. So whether you're an old or new friend, do stop by and say hello! Going to AAIC? Drop us a message and let us know, maybe we can schedule a time to talk! See you in Philadelphia!

Join us tomorrow for an insightful discussion on overcoming key challenges in Alzheimer's disease (AD) research, particularly the low recruitment rates of underrepresented populations. This gap limits the effectiveness of treatments across diverse demographics. Learn how improving recruitment strategies and leveraging advanced imaging biomarkers like amyloid PET can enhance AD clinical trial design. What You’ll Learn: 🔹 Inclusive Research: The importance of diversity in clinical trials, with insights from the Bio-Hermes study. 🔹Equity in Healthcare: How diverse participation leads to more equitable healthcare solutions. 🔹Neuroimaging: Interpretation of PET imaging biomarkers in multi-center clinical trials. Webinar Details: 📅 Date: Tuesday, June 25th, 2024 🕓 Time: 3pm BST / 4pm CET / 10am EDT 🎙️ Speakers: ➡ Richard Mohs, Chief Science Officer – Global Alzheimer's Platform Foundation ➡ Robin Wolz, Chief Scientific Officer – IXICO Register here:https://lnkd.in/gfgz68St